Regeneron’s REGN-COV2 is first antibody cocktail for COVID-19 to receive FDA emergency use authorization

Dear Investor,

Please find attached a press release from our partner Regeneron:

https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive

For further information please also have a look at the attached Roche statement on FDA acceptance of casirivimab and imdevimab (REGN-COV2) EUA in the US.

Do not hesitate to contact us for any further questions.


With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com	Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com	Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com

 

Attachment

• 201123_Media statement on REGN-COV2 EUA acceptance